Search hospitals

>

Kansas

>

Newton

Cancer Center of Kansas - Newton

Claim this profile

Newton, Kansas 67114

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Cancer

Conducts research for Lymphoma

387 reported clinical trials

9 medical researchers

Photo of Cancer Center of Kansas - Newton in NewtonPhoto of Cancer Center of Kansas - Newton in Newton

Summary

Cancer Center of Kansas - Newton is a medical facility located in Newton, Kansas. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Lymphoma and other specialties. Cancer Center of Kansas - Newton is involved with conducting 387 clinical trials across 422 conditions. There are 9 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Dennis F. Moore, Eric Whitman, MD, and Charles M Farber, MD.

Area of expertise

1

Breast Cancer

Global Leader

Cancer Center of Kansas - Newton has run 89 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
HER2 positive
2

Lung Cancer

Global Leader

Cancer Center of Kansas - Newton has run 59 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage IV

Top PIs

Clinical Trials running at Cancer Center of Kansas - Newton

Lung Cancer

Breast Cancer

Bladder Cancer

Breast cancer

Prostate Cancer

Bladder Carcinoma

Ovarian Cancer

Multiple Myeloma

Cancer

Colorectal Cancer

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Recruiting

2 awards

Phase 3

10 criteria

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cancer Center of Kansas - Newton?

Where is Cancer Center of Kansas - Newton located?

Who should I call to ask about financial aid or insurance network?

What insurance does Cancer Center of Kansas - Newton accept?

What awards or recognition has Cancer Center of Kansas - Newton received?